-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Since Bristol-Myers Squibb bought Celgene and its superblockbuster Revlimid (lenalidomide) for $74 billion in 2019, the company has been facing generics for the multiple myeloma star drug Prepare for the day of the shock
.
In many European countries, that day has come
On Friday, Novartis’ generics company Sandoz announced that it had launched a generic version of Revlimid in 19 European countries
.
German generic drug maker Stada Arzneimittel has also reportedly launched a generic version of Revlimid in Europe
Sandoz said the generic version of Revlimid will provide cost savings for patients and healthcare systems and expand treatment options for patients with multiple myeloma, follicular lymphoma, myelodysplastic syndrome, and mantle cell lymphoma
.
Sandoz is Europe's largest generic drug maker, with global sales of $9.
8 billion last year
.
Sandoz is also Europe's No.
The company's growing portfolio now covers 75% of the molecules in the World Health Organization (WHO) global Oncology Essential Medicines List, an industry-leading position
.
Last September, Sandoz launched a generic version of Revlimid in Canada
.
Meanwhile, the first generic versions of Revlimid are scheduled to enter the world's largest pharmaceutical market, the United States, next month
Revlimid will bring in $12.
8 billion in sales in 2021, according to an earnings report released by Bristol-Myers Squibb
.
Bristol-Myers Squibb expects Revlimid's global sales to fall to between $9.
Celgene has worked to avoid generic competition through court battles and settlements since Revlimid was originally approved in 2006
.
In some smaller European markets, though, Alvogen has already launched a generic version of Revlimid in 2019
Reference source: Sandoz, Stada launch generic Revlimid in Europe
